General description
Janus kinase 1 (JAK1) is encoded by the gene mapped to human chromosome 1p31.3. The encoded protein is one of the four members of the mammalian JAK families. Members of JAK family contain an N-terminal FERM (four.1, ezrin, radixin, moesin) domain, through which they interact with cytokine receptors. The N-terminal end also contains an SH2-like domain. In addition, it also contains a kinase domain and a pseudo-kinase domain, which is catalytically inactive. JAK1 is ubiquitously expressed. When expressed without their receptors, JAKs reside in the cytosol. However, under normal cell conditions, they localize to plasma membrane and endosomes.
Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor.
Immunogen
Peptide sequence around phosphorylation site of tyrosine 1022 (K-E-Y(p)-Y-T), according to the protein JAK1.
Application
Anti-phospho-JAK1 (pTyr1022) antibody produced in rabbit has been used in Western blot analysis.
Biochem/physiol Actions
Janus kinases (JAKs) are activated when cytokines bind with their receptors, upon which they phosphorylate the receptors and produce docking sites for signaling molecules. One of the main signaling molecules includes signal transducer and activator of transcription (Stat) family. JAK1 is needed by multiple cytokines, including the family using the shared receptor subunit called common γ chain (γc), such as interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15 and IL-21. JAK1 KO (knockout) mice have early postnatal lethal or perinatal lethal phenotype due to neurological defects. In vitro studies show that JAK1S703I mutation functions as an activator of JAK-STAT pathways even in the absence of cytokines, and drives cellular proliferation. JAK1S703I mutant patient-derived xenograft (PDX) HCC (hepatocellular carcinoma) cells also show sensitivity to JAK1/2 inhibitor, ruxolitinib.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
| biological source | rabbit |
| Quality Segment | 100 |
| conjugate | unconjugated |
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| clone | polyclonal |
| form | buffered aqueous solution |
| mol wt | ~130 kDa |
| species reactivity | rat, mouse, human |
| concentration | 1 mg/mL |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:100,western blot: 1:500-1:1000 |
| isotype | IgG |
| immunogen sequence | (K-E-YP-Y-T) |
| NCBI accession no. | NP_002218.2 |
| UniProt accession no. | P23458 |
| shipped in | wet ice |
| storage temp. | −20°C |
| target post-translational modification | phosphorylation (pTyr1022) |
| Gene Information | human ... JAK1(3716) |
